Molecular Neurobiology

, Volume 55, Issue 5, pp 4207–4224 | Cite as

Downregulated Glia Interplay and Increased miRNA-155 as Promising Markers to Track ALS at an Early Stage

  • Carolina Cunha
  • Catarina Santos
  • Cátia Gomes
  • Adelaide Fernandes
  • Alexandra Marçal Correia
  • Ana Maria Sebastião
  • Ana Rita Vaz
  • Dora Brites
Article

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of unknown cause. Absence of specific targets and biomarkers compromise the development of new therapeutic strategies and of innovative tools to stratify patients and assess their responses to treatment. Here, we investigate changes in neuroprotective-neuroinflammatory actions in the spinal cord of SOD1 G93A mice, at presymptomatic and symptomatic stages to identify stage-specific biomarkers and potential targets. Results showed that in the presymptomatic stage, there are alterations in both astrocytes and microglia, which comprise decreased expression of GFAP and S100B and upregulation of GLT-1, as well as reduced expression of CD11b, M2-phenotype markers, and a set of inflammatory mediators. Reduced levels of Connexin-43, Pannexin-1, CCL21, and CX3CL1 further indicate the existence of a compromised intercellular communication. In contrast, in the symptomatic stage, increased markers of inflammation became evident, such as NF-κB/Nlrp3-inflammasome, Iba1, pro-inflammatory cytokines, and M1-polarizion markers, together with a decreased expression of M2-phenotypic markers. We also observed upregulation of the CX3CL1-CX3CR1 axis, Connexin-43, Pannexin-1, and of microRNAs (miR)-124, miR-125b, miR-146a and miR-21. Reduced motor neuron number and presence of reactive astrocytes with decreased GFAP, GLT-1, and GLAST further characterized this inflammatory stage. Interestingly, upregulation of miR-155 and downregulation of MFG-E8 appear as consistent biomarkers of both presymptomatic and symptomatic stages. We hypothesize that downregulated cellular interplay at the early stages may represent neuroprotective mechanisms against inflammation, SOD1 aggregation, and ALS onset. The present study identified a set of inflamma-miRNAs, NLRP3-inflammasome, HMGB1, CX3CL1-CX3CR1, Connexin-43, and Pannexin-1 as emerging candidates and promising pharmacological targets that may represent potential neuroprotective strategies in ALS therapy.

Keywords

Inflamma-miRNAs Transgenic SOD1G93A mice Presymptomatic and symptomatic stages Astrocytes and microglia function Motor neuron-glia communication ALS biomarkers 

Abbreviations

ALS

Amyotrophic lateral sclerosis

Arg1

Arginase 1

Cebpa

CCAAT/enhancer-binding protein alpha

CCL21

Chemokine (C-C motif) ligand 21

CCR7

Chemokine (C-C motif) receptor type 7

CSF

Cerebrospinal fluid

CX3CL1

Chemokine (C-X3-C motif) ligand 1

CX3CR1

Chemokine (C-X3-C motif) receptor 1

Cx43

Connexin-43

GFAP

Glial fibrillary acidic protein

GLT-1

Glutamate transporter 1

Fizz1

Found in inflammatory zone 1

HMGB1

High mobility group box 1

H&E

hematoxylin–eosin

Iba1

Ionized calcium-binding adapter molecule 1

IL

Interleukin

miR

MicroRNA

MFG-E8

Milk fat globule-EGF factor 8

NeuN

Neuronal nuclei

NF-κB

Nuclear factor kappa B

NLRP3

NOD-like receptor family pyrin domain containing 3

Panx1

Pannexin-1

PBS

Phosphate buffer saline

pNF-κB

Phosphorylated NF-κB

qRT-PCR

Quantitative reverse transcription polymerase chain reaction

RT

Room temperature

S100B

S100 calcium-binding protein B

SC

Spinal cord

SOCS1

Suppressor of cytokine signaling 1

SOD1

Superoxide dismutase 1

TLRs

Toll-like receptors

TGF-β

Transforming growth factor beta

TNF-α

Tumor necrosis factor alfa

WB

Western blot

WT

Wild type

Notes

Acknowledgements

This work was funded by the Research Grant of the Santa Casa Scientific Research Program on ALS, by Santa Casa da Misericórdia de Lisboa (SCML), Portugal, Project Ref. ELA-2015-002 (to DB), by the project PTDC/SAU-FAR/118787/2010 (to D.B.) and, in part, by iMed.ULisboa (UID/DTP/04138/2013) from Fundação para a Ciência e a Tecnologia (FCT). A.R.V. holds a postdoctoral research fellowship (SFRH/BPD/76590/2011), and C.C. and C.G. are recipients of PhD fellowships (SFRH/BD/91316/2012 and SFRH/BD/102718/2014, respectively), all from FCT. The funding organization had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank to Dr. Rui Gomes (Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Portugal) for genotyping mice.

Author’s Contributions

D.B, conceived the study; D.B. and A.R.V. designed the experiments; A.R.V. gave technical support; C.C., C.G., A.R.V., A.F. and C.S. acquired data; A.S. and A.M.C. contributed to conceptual advice and data acquisition on mice related with its usage, management, and maintenance; A.R.V., C.C., and D.B. analyzed data; C.C. and A.R.V. drafted figures and participated in the manuscript writing; D.B. wrote and edited the final version. The manuscript has been read and approved by all named authors.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

12035_2017_631_MOESM1_ESM.doc (54 kb)
Supplementary Table 1 (DOC 53 kb)
12035_2017_631_MOESM2_ESM.doc (66 kb)
Supplementary Table 2 (DOC 66 kb)

References

  1. 1.
    Benatar M, Wuu J (2012) Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 79(16):1732–1739. doi: 10.1212/WNL.0b013e31826e9b1d CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rocha MC, Pousinha PA, Correia AM, Sebastiao AM, Ribeiro JA (2013) Early changes of neuromuscular transmission in the SOD1(G93A) mice model of ALS start long before motor symptoms onset. PLoS One 8(9):e73846. doi: 10.1371/journal.pone.0073846 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Nascimento F, Pousinha PA, Correia AM, Gomes R, Sebastiao AM, Ribeiro JA (2014) Adenosine A2A receptors activation facilitates neuromuscular transmission in the pre-symptomatic phase of the SOD1(G93A) ALS mice, but not in the symptomatic phase. PLoS One 9(8):e104081. doi: 10.1371/journal.pone.0104081 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Nascimento F, Sebastiao AM, Ribeiro JA (2015) Presymptomatic and symptomatic ALS SOD1(G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission. Purinergic Signal 11(4):471–480. doi: 10.1007/s11302-015-9465-4 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gravel M, Beland LC, Soucy G, Abdelhamid E, Rahimian R, Gravel C, Kriz J (2016) IL-10 controls early microglial phenotypes and disease onset in ALS caused by misfolded superoxide dismutase 1. J Neurosci 36(3):1031–1048. doi: 10.1523/JNEUROSCI.0854-15.2016 CrossRefPubMedGoogle Scholar
  6. 6.
    Tefera TW, Wong Y, Barkl-Luke ME, Ngo ST, Thomas NK, McDonald TS, Borges K (2016) Triheptanoin protects motor neurons and delays the onset of motor symptoms in a mouse model of amyotrophic lateral sclerosis. PLoS One 11(8):e0161816. doi: 10.1371/journal.pone.0161816 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Apolloni S, Fabbrizio P, Amadio S, Volonte C (2016) Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression. J Neuroinflammation 13(1):191. doi: 10.1186/s12974-016-0658-8 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, Bestwick JP, Monsch AU et al (2013) Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 8(9):e75091. doi: 10.1371/journal.pone.0075091 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, Bottacchi E, Mutani R (2002) Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59(1):99–103CrossRefPubMedGoogle Scholar
  10. 10.
    Turner M, Al-Chalabi A (2002) Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59(12):2012–2013 author reply 2013 CrossRefPubMedGoogle Scholar
  11. 11.
    Benatar M, Stanislaw C, Reyes E, Hussain S, Cooley A, Fernandez MC, Dauphin DD, Michon SC et al (2016) Presymptomatic ALS genetic counseling and testing: experience and recommendations. Neurology 86(24):2295–2302. doi: 10.1212/WNL.0000000000002773 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, Leigh PN, Banati RB (2004) Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15(3):601–609. doi: 10.1016/j.nbd.2003.12.012 CrossRefPubMedGoogle Scholar
  13. 13.
    Brites D, Vaz AR (2014) Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front Cell Neurosci 8:117. doi: 10.3389/fncel.2014.00117 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hensley K, Floyd RA, Gordon B, Mou S, Pye QN, Stewart C, West M, Williamson K (2002) Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 82(2):365–374CrossRefPubMedGoogle Scholar
  15. 15.
    Casula M, Iyer AM, Spliet WG, Anink JJ, Steentjes K, Sta M, Troost D, Aronica E (2011) Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 179:233–243. doi: 10.1016/j.neuroscience.2011.02.001 CrossRefPubMedGoogle Scholar
  16. 16.
    Lee JY, Lee JD, Phipps S, Noakes PG, Woodruff TM (2015) Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 12:90. doi: 10.1186/s12974-015-0310-z CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lo Coco D, Veglianese P, Allievi E, Bendotti C (2007) Distribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALS. Neurosci Lett 412(1):73–77. doi: 10.1016/j.neulet.2006.10.063 CrossRefPubMedGoogle Scholar
  18. 18.
    Johann S, Heitzer M, Kanagaratnam M, Goswami A, Rizo T, Weis J, Troost D, Beyer C (2015) NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia 63(12):2260–2273. doi: 10.1002/glia.22891 CrossRefPubMedGoogle Scholar
  19. 19.
    Campos-Melo D, Droppelmann CA, He Z, Volkening K, Strong MJ (2013) Altered microRNA expression profile in amyotrophic lateral sclerosis: a role in the regulation of NFL mRNA levels. Molecular brain 6:26. doi: 10.1186/1756-6606-6-26 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Koval ED, Shaner C, Zhang P, du Maine X, Fischer K, Tay J, Chau BN, Wu GF et al (2013) Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet 22(20):4127–4135. doi: 10.1093/hmg/ddt261 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, Greco DJ, Wu PM et al (2015) Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol 77(1):75–99. doi: 10.1002/ana.24304 CrossRefPubMedGoogle Scholar
  22. 22.
    ALSA (2017) miRagen therapeutics receives ALS Association grant to advance the development of MRG-107. http://www.alsa.org/news/media/press-releases/miragen-therapeutics-060216.html.
  23. 23.
    Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A et al (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264(5166):1772–1775CrossRefPubMedGoogle Scholar
  24. 24.
    Cardoso FL, Herz J, Fernandes A, Rocha J, Sepodes B, Brito MA, McGavern DB, Brites D (2015) Systemic inflammation in early neonatal mice induces transient and lasting neurodegenerative effects. J Neuroinflammation 12:82. doi: 10.1186/s12974-015-0299-3 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Simões AE, Pereira DM, Amaral JD, Nunes AF, Gomes SE, Rodrigues PM, Lo AC, D'Hooge R et al (2013) Efficient recovery of proteins from multiple source samples after TRIzol((R)) or TRIzol((R))LS RNA extraction and long-term storage. BMC Genomics 14:181. doi: 10.1186/1471-2164-14-181 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Fernandes A, Falcão AS, Silva RF, Gordo AC, Gama MJ, Brito MA, Brites D (2006) Inflammatory signalling pathways involved in astroglial activation by unconjugated bilirubin. J Neurochem 96(6):1667–1679. doi: 10.1111/j.1471-4159.2006.03680.x CrossRefPubMedGoogle Scholar
  27. 27.
    Caldeira C, Oliveira AF, Cunha C, Vaz AR, Falcão AS, Fernandes A, Brites D (2014) Microglia change from a reactive to an age-like phenotype with the time in culture. Front Cell Neurosci 8:152. doi: 10.3389/fncel.2014.00152 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cunha C, Gomes C, Vaz AR, Brites D (2016) Exploring new inflammatory biomarkers and pathways during LPS-induced M1 polarization. Mediat Inflamm 2016:6986175. doi: 10.1155/2016/6986175 CrossRefGoogle Scholar
  29. 29.
    Pathak S, Grillo AR, Scarpa M, Brun P, D'Inca R, Nai L, Banerjee A, Cavallo D et al (2015) MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis. Exp Mol Med 47:e164. doi: 10.1038/emm.2015.21 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    de Jong EK, Dijkstra IM, Hensens M, Brouwer N, van Amerongen M, Liem RS, Boddeke HW, Biber K (2005) Vesicle-mediated transport and release of CCL21 in endangered neurons: a possible explanation for microglia activation remote from a primary lesion. J Neurosci 25(33):7548–7557. doi: 10.1523/JNEUROSCI.1019-05.2005 CrossRefPubMedGoogle Scholar
  31. 31.
    Díaz-Amarilla P, Olivera-Bravo S, Trias E, Cragnolini A, Martinez-Palma L, Cassina P, Beckman J, Barbeito L (2011) Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 108(44):18126–18131. doi: 10.1073/pnas.1110689108 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Vargas MR, Johnson JA (2010) Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics 7(4):471–481. doi: 10.1016/j.nurt.2010.05.012 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Awada R, Rondeau P, Gres S, Saulnier-Blache JS, Lefebvre d'Hellencourt C, Bourdon E (2012) Autotaxin protects microglial cells against oxidative stress. Free Radic Biol Med 52(2):516–526. doi: 10.1016/j.freeradbiomed.2011.11.014 CrossRefPubMedGoogle Scholar
  34. 34.
    Chiu IM, Morimoto ET, Goodarzi H, Liao JT, O'Keeffe S, Phatnani HP, Muratet M, Carroll MC et al (2013) A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep 4(2):385–401. doi: 10.1016/j.celrep.2013.06.018 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Li X, Kong D, Chen H, Liu S, Hu H, Wu T, Wang J, Chen W, Ning Y, Li Y, Lu Z (2016) miR-155 acts as an anti-inflammatory factor in atherosclerosis-associated foam cell formation by repressing calcium-regulated heat stable protein 1. Scientific reports 6:21789. doi: 10.1038/srep21789
  36. 36.
    Raymond A, Ensslin MA, Shur BD (2009) SED1/MFG-E8: a bi-motif protein that orchestrates diverse cellular interactions. J Cell Biochem 106(6):957–966. doi: 10.1002/jcb.22076 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Liu Y, Yang X, Guo C, Nie P, Liu Y, Ma J (2013) Essential role of MFG-E8 for phagocytic properties of microglial cells. PLoS One 8(2):e55754. doi: 10.1371/journal.pone.0055754 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Suzuki M, El-Hage N, Zou S, Hahn YK, Sorrell ME, Sturgill JL, Conrad DH, Knapp PE et al (2011) Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death. Mol Neurodegener 6:78. doi: 10.1186/1750-1326-6-78 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Sheridan GK, Murphy KJ (2013) Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open biology 3(12):130181. doi: 10.1098/rsob.130181 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, Doykan CE, Wu PM et al (2012) Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 122(9):3063–3087. doi: 10.1172/JCI62636 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Oak S, Mandrekar P, Catalano D, Kodys K, Szabo G (2006) TLR2- and TLR4-mediated signals determine attenuation or augmentation of inflammation by acute alcohol in monocytes. J Immunol 176(12):7628–7635CrossRefPubMedGoogle Scholar
  42. 42.
    Volonté C, Apolloni S, Parisi C (2015) MicroRNAs: newcomers into the ALS picture. CNS Neurol Disord Drug Targets 14(2):194–207CrossRefPubMedGoogle Scholar
  43. 43.
    Ponomarev ED, Veremeyko T, Weiner HL (2013) MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS. Glia 61(1):91–103. doi: 10.1002/glia.22363 CrossRefPubMedGoogle Scholar
  44. 44.
    Saba R, Gushue S, Huzarewich RL, Manguiat K, Medina S, Robertson C, Booth SA (2012) MicroRNA 146a (miR-146a) is over-expressed during prion disease and modulates the innate immune response and the microglial activation state. PLoS One 7(2):e30832. doi: 10.1371/journal.pone.0030832 CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL (2011) MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med 17(1):64–70. doi: 10.1038/nm.2266 CrossRefPubMedGoogle Scholar
  46. 46.
    Limatola C, Ransohoff RM (2014) Modulating neurotoxicity through CX3CL1/CX3CR1 signaling. Front Cell Neurosci 8:229. doi: 10.3389/fncel.2014.00229 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Zabel MK, Zhao L, Zhang Y, Gonzalez SR, Ma W, Wang X, Fariss RN, Wong WT (2016) Microglial phagocytosis and activation underlying photoreceptor degeneration is regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa. Glia 64(9):1479–1491. doi: 10.1002/glia.23016 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Vu LT, Bowser R (2016) Fluid-based biomarkers for amyotrophic lateral sclerosis. Neurotherapeutics. doi: 10.1007/s13311-016-0503-x
  49. 49.
    Cardoso AL, Guedes JR, Pereira de Almeida L, Pedroso de Lima MC (2012) miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology 135(1):73–88. doi: 10.1111/j.1365-2567.2011.03514.x CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Guedes JR, Custodia CM, Silva RJ, de Almeida LP, Pedroso de Lima MC, Cardoso AL (2014) Early miR-155 upregulation contributes to neuroinflammation in Alzheimer’s disease triple transgenic mouse model. Hum Mol Genet 23(23):6286–6301. doi: 10.1093/hmg/ddu348 CrossRefPubMedGoogle Scholar
  51. 51.
    Czochor JR, Sulkowski P, Glazer PM (2016) miR-155 overexpression promotes genomic instability by reducing high-fidelity polymerase delta expression and activating error-prone DSB repair. Mol Cancer Res 14(4):363–373. doi: 10.1158/1541-7786.MCR-15-0399 CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Yuan K, Zhang X, Lv L, Zhang J, Liang W, Wang P (2016) Fine-tuning the expression of microRNA-155 controls acetaminophen-induced liver inflammation. Int Immunopharmacol 40:339–346. doi: 10.1016/j.intimp.2016.09.011 CrossRefPubMedGoogle Scholar
  53. 53.
    Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G et al (2006) Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9(7):917–924. doi: 10.1038/nn1715 CrossRefPubMedGoogle Scholar
  54. 54.
    Fricker M, Neher JJ, Zhao JW, Thery C, Tolkovsky AM, Brown GC (2012) MFG-E8 mediates primary phagocytosis of viable neurons during neuroinflammation. J Neurosci 32(8):2657–2666. doi: 10.1523/JNEUROSCI.4837-11.2012 CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S (2002) Identification of a factor that links apoptotic cells to phagocytes. Nature 417(6885):182–187. doi: 10.1038/417182a CrossRefPubMedGoogle Scholar
  56. 56.
    Das A, Ghatak S, Sinha M, Chaffee S, Ahmed NS, Parinandi NL, Wohleb ES, Sheridan JF et al (2016) Correction of MFG-E8 resolves inflammation and promotes cutaneous wound healing in diabetes. J Immunol 196(12):5089–5100. doi: 10.4049/jimmunol.1502270 CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Parisi C, Napoli G, Amadio S, Spalloni A, Apolloni S, Longone P, Volonte C (2016) MicroRNA-125b regulates microglia activation and motor neuron death in ALS. Cell Death Differ 23(3):531–541. doi: 10.1038/cdd.2015.153 CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    He X, Jing Z, Cheng G (2014) MicroRNAs: new regulators of Toll-like receptor signalling pathways. Biomed Res Int 2014:945169. doi: 10.1155/2014/945169 PubMedPubMedCentralGoogle Scholar
  59. 59.
    Sun Y, Luo ZM, Guo XM, Su DF, Liu X (2015) An updated role of microRNA-124 in central nervous system disorders: a review. Front Cell Neurosci 9:193. doi: 10.3389/fncel.2015.00193 CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Pinto S, Cunha C, Barbosa M, Vaz AR, Brites D (2017) Exosomes from NSC-34 cells transfected with hSOD1-G93A are enriched in miR-124 and drive alterations in microglia phenotype. Front Neurosci 11:273. doi: 10.3389/fnins.2017.00273 CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Thomsen GM, Gowing G, Latter J, Chen M, Vit JP, Staggenborg K, Avalos P, Alkaslasi M et al (2014) Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci 34(47):15587–15600. doi: 10.1523/JNEUROSCI.2037-14.2014 CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Kuo JJ, Schonewille M, Siddique T, Schults AN, Fu R, Bar PR, Anelli R, Heckman CJ et al (2004) Hyperexcitability of cultured spinal motoneurons from presymptomatic ALS mice. J Neurophysiol 91(1):571–575. doi: 10.1152/jn.00665.2003 CrossRefPubMedGoogle Scholar
  63. 63.
    Vucic S, Nicholson GA, Kiernan MC (2008) Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 131(Pt 6):1540–1550. doi: 10.1093/brain/awn071 CrossRefPubMedGoogle Scholar
  64. 64.
    Ciryam P, Kundra R, Freer R, Morimoto RI, Dobson CM, Vendruscolo M (2016) A transcriptional signature of Alzheimer’s disease is associated with a metastable subproteome at risk for aggregation. Proc Natl Acad Sci U S A 113(17):4753–4758. doi: 10.1073/pnas.1516604113 CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312(5778):1389–1392. doi: 10.1126/science.1123511 CrossRefPubMedGoogle Scholar
  66. 66.
    Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, Ladner KJ, Bevan AK et al (2014) Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron 81(5):1009–1023. doi: 10.1016/j.neuron.2014.01.013 CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Nikodemova M, Small AL, Smith SMC, Mitchell GS, Watters JJ (2014) Spinal but not cortical microglia acquire an atypical phenotype with high VEGF, galectin-3 and osteopontin, and blunted inflammatory responses in ALS rats. Neurobiol Dis 69:43–53. doi: 10.1016/j.nbd.2013.11.009 CrossRefPubMedGoogle Scholar
  68. 68.
    Montero TD, Orellana JA (2015) Hemichannels: new pathways for gliotransmitter release. Neuroscience 286:45–59. doi: 10.1016/j.neuroscience.2014.11.048 CrossRefPubMedGoogle Scholar
  69. 69.
    Orellana JA, Froger N, Ezan P, Jiang JX, Bennett MV, Naus CC, Giaume C, Saez JC (2011) ATP and glutamate released via astroglial connexin 43 hemichannels mediate neuronal death through activation of pannexin 1 hemichannels. J Neurochem 118(5):826–840. doi: 10.1111/j.1471-4159.2011.07210.x CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Chen SC, Leach MW, Chen Y, Cai XY, Sullivan L, Wiekowski M, Dovey-Hartman BJ, Zlotnik A et al (2002) Central nervous system inflammation and neurological disease in transgenic mice expressing the CC chemokine CCL21 in oligodendrocytes. J Immunol 168(3):1009–1017CrossRefPubMedGoogle Scholar
  71. 71.
    Wolf Y, Yona S, Kim KW, Jung S (2013) Microglia, seen from the CX3CR1 angle. Front Cell Neurosci 7:26. doi: 10.3389/fncel.2013.00026 CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Wu J, Bie B, Yang H, Xu JJ, Brown DL, Naguib M (2013) Suppression of central chemokine fractalkine receptor signaling alleviates amyloid-induced memory deficiency. Neurobiol Aging 34(12):2843–2852. doi: 10.1016/j.neurobiolaging.2013.06.003 CrossRefPubMedGoogle Scholar
  73. 73.
    Lopez-Lopez A, Gamez J, Syriani E, Morales M, Salvado M, Rodriguez MJ, Mahy N, Vidal-Taboada JM (2014) CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis. PLoS One 9(5):e96528. doi: 10.1371/journal.pone.0096528 CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ (2000) Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci 20(15):RC87PubMedGoogle Scholar
  75. 75.
    Zahednasab H, Balood M, Harirchian MH, Mesbah-Namin SA, Rahimian N, Siroos B (2014) Increased autotaxin activity in multiple sclerosis. J Neuroimmunol 273(1–2):120–123. doi: 10.1016/j.jneuroim.2014.06.006 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Neuron Glia Biology in Health and Disease Group, Research Institute for Medicines (iMed.ULisboa), Faculty of PharmacyUniversidade de LisboaLisbonPortugal
  2. 2.Department of Biochemistry and Human Biology, Faculty of PharmacyUniversidade de LisboaLisbonPortugal
  3. 3.Museu Nacional de História Natural e da CiênciaUniversidade de LisboaLisbonPortugal
  4. 4.Instituto de Farmacologia e Neurociências, Faculdade de MedicinaUniversidade de LisboaLisboaPortugal
  5. 5.Instituto de Medicina Molecular, Faculdade de MedicinaUniversidade de LisboaLisboaPortugal

Personalised recommendations